These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8196119)

  • 1. Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients.
    Petronis KR; Carroll CE; Held PJ; Port FK
    JAMA; 1994 Jun; 271(22):1760-3. PubMed ID: 8196119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race and access to erythropoietin by patients on hemodialysis.
    Sadler JH
    JAMA; 1994 Dec; 272(23):1818-9. PubMed ID: 7990207
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of race with erythropoietin dose in patients on long-term hemodialysis.
    Lacson E; Rogus J; Teng M; Lazarus JM; Hakim RM
    Am J Kidney Dis; 2008 Dec; 52(6):1104-14. PubMed ID: 18824287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender modulates responsiveness to recombinant erythropoietin.
    Ifudu O; Uribarri J; Rajwani I; Vlacich V; Reydel K; Delosreyes G; Friedman EA
    Am J Kidney Dis; 2001 Sep; 38(3):518-22. PubMed ID: 11532683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial differences in choice of dialysis modality for children with end-stage renal disease.
    Furth SL; Powe NR; Hwang W; Neu AM; Fivush BA
    Pediatrics; 1997 Apr; 99(4):E6. PubMed ID: 9099781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of AIDS and the response to EPO in uremia.
    Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
    Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD.
    Yan G; Cheung AK; Ma JZ; Yu AJ; Greene T; Oliver MN; Yu W; Norris KC
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):610-8. PubMed ID: 23493380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
    Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
    Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ethnicity on erythropoietin therapy response for hemodialysis patients: a retrospective study.
    Al-Khalaf B; Al-Khalaf N; Mustafa S
    Hemodial Int; 2013 Oct; 17(4):510-6. PubMed ID: 23095132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional variation in health care intensity and treatment practices for end-stage renal disease in older adults.
    O'Hare AM; Rodriguez RA; Hailpern SM; Larson EB; Kurella Tamura M
    JAMA; 2010 Jul; 304(2):180-6. PubMed ID: 20628131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients.
    Ifudu O; Macey LJ; Friedman EA
    ASAIO J; 1995; 41(3):M426-30. PubMed ID: 8573839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.